Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma

Cancer
Tom PicklesBritish Columbia Cancer Agency, Prostate Cohort Outcomes Initiative

Abstract

This study was conducted to describe the rate and completeness of the recovery of testosterone production following prolonged temporary androgen ablative therapy in men with prostate carcinoma undergoing curative radiation therapy. Two-hundred and sixty-seven men treated with between 3 months and 3 years of adjuvant androgen ablation (AA) were followed at 6-month intervals following cessation of their androgen deprivation therapy. A comparative group of 518 men not undergoing AA were also followed. Drugs used included low dose cyproterone/stilboestrol (CPA/DES) in combination (56%) and 1 month depot (18%) and 3 month depot (25%) leutinizing hormone releasing hormone agonist (LHRHa). Seventy-nine percent of men in the current study recovered normal testosterone levels (10nmol/L), and 93% recovered levels of at least 5nmol/L. In comparison, men who had never received androgen ablative therapy showed a fall of testosterone, with 17% having sub-normal levels after 3 years. Median time to testosterone recovery was 10 months. Factors associated on multivariate analysis with delayed testosterone recovery included advanced age (P = 0.008), low pre-therapy testosterone (P = 0.04), and the use of 3 month LHRHa preparations as compared wi...Continue Reading

References

Jan 1, 1995·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·M A Izard
Jul 29, 1998·The Journal of Urology·L R MillerP C Walsh
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·U Keilholz
Aug 5, 2000·Clinical Pharmacokinetics·I D Cockshott

❮ Previous
Next ❯

Citations

Aug 10, 2006·Journal of Cancer Research and Clinical Oncology·William A SeeUNKNOWN CASODEX Early Prostate Cancer Trialists' Group
Mar 3, 2011·Current Urology Reports·Tanya B Dorff, Nicholas J Vogelzang
Jun 7, 2005·International Journal of Radiation Oncology, Biology, Physics·Anthony L ZietmanWilliam U Shipley
Jun 18, 2003·Urologic Oncology·Eila C Skinner, L Michael Glode
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DecensiBernardo Bonanni
Jun 16, 2011·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Howard Huaihan PaiEric Berthelet
Jun 10, 2010·Future Oncology·Kai-Keen ShiuJorge S Reis-Filho
Apr 12, 2014·British Journal of Cancer·T NomiyaUNKNOWN Working Group for Genitourinary Tumors
Apr 26, 2011·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·A FaureC Coulange
Mar 15, 2008·European Urology·Jacques IraniUNKNOWN Association for Research in Urological Oncology
Sep 25, 2014·Journal of Geriatric Oncology·Deepak KilariSupriya Gupta Mohile
Sep 19, 2012·Seminars in Radiation Oncology·Ronald C ChenBryce B Reeve
Oct 14, 2011·Clinical Genitourinary Cancer·Mark C ScholzRobert I Jennrich
May 18, 2010·International Journal of Radiation Oncology, Biology, Physics·Scott WilliamsTom Pickles
Sep 22, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Claudio FiorinoGiuseppe Sanguineti
Aug 1, 2009·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·G CazoulatP Haigron
Jul 7, 2009·International Journal of Radiation Oncology, Biology, Physics·James W DenhamCatherine D'Este
Dec 20, 2008·International Journal of Radiation Oncology, Biology, Physics·Frederick H YoonLarry Stitt
Aug 20, 2008·The Journal of Urology·Frederick H YoonRichard Choo
Oct 28, 2008·Critical Reviews in Oncology/hematology·Supriya G MohileWilliam Dale
Apr 27, 2005·International Journal of Radiation Oncology, Biology, Physics·Andrew Tom BatesChuck Paltiel
Jun 9, 2004·International Journal of Radiation Oncology, Biology, Physics·Barby PickettMack Roach
May 30, 2006·International Journal of Radiation Oncology, Biology, Physics·Scott G WilliamsGary Pratt
Nov 18, 2005·International Journal of Radiation Oncology, Biology, Physics·Fabio L B CuryCarolyn R Freeman
May 20, 2015·The Journal of Urology·Mohamed JallohPeter R Carroll
Jan 25, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Julia J van Tol-GeerdinkPeep F M Stalmeier
Apr 19, 2015·Japanese Journal of Clinical Oncology·Hiromitsu KanzakiKatsuyoshi Hashine
Jul 2, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Hans GeinitzMichael Molls

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.